OverviewSuggest Edit

Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, U.K. developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals. Bicycle technology is based on discoveries made at the MRC Laboratory of Molecular Biology in Cambridge by co-founders, Professor Christian Heinis and Sir Gregory Winter, which have been developed at the company into a robust technology platform under the leadership of Dr. John Tite (CSO). 
TypePublic
HQBabraham, GB
Websitebicycletherapeutics.com

Latest Updates

Employees (est.) (Sept 2019)67(+10%)
Job Openings8
Revenue (FY, 2019)$13.8 M(+94%)
Share Price (Oct 2020)$19
Cybersecurity ratingAMore

Key People/Management at Bicycle Therapeutics

Kevin Lee

Kevin Lee

CEO, Director
Kate Bingham

Kate Bingham

Director
Lee Kalowski

Lee Kalowski

President and Chief Financial Officer
Nick Keen

Nick Keen

Chief Scientific Officer
Greg Winter

Greg Winter

Co-Founder, Director, Advisor
Michael Skynner

Michael Skynner

COO
Show more

Bicycle Therapeutics Office Locations

Bicycle Therapeutics has offices in Babraham and Lexington
Babraham, GB (HQ)
Meditrina Building, Babraham Research Campus
Lexington, US
4 Hartwell Pl
Show all (2)

Bicycle Therapeutics Financials and Metrics

Bicycle Therapeutics Revenue

Bicycle Therapeutics's revenue was reported to be $13.80 m in FY, 2019
USD

Revenue (Q2, 2020)

1.6m

Net income (Q2, 2020)

(12.1m)

EBIT (Q2, 2020)

(12.6m)

Market capitalization (23-Oct-2020)

366.2m

Closing stock price (23-Oct-2020)

19.0

EV

367.1m
Bicycle Therapeutics's current market capitalization is $366.2 m.
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

836.1k81.1k45.0k2.1m7.1m13.8m

Revenue growth, %

246%

General and administrative expense

6.4m8.1m14.6m

R&D expense

11.9m70.8m25.5m
Quarterly
USDQ2, 2019Q3, 2019Q2, 2020

Revenue

1.5m614.0k1.6m

General and administrative expense

3.0m4.8m6.2m

R&D expense

6.5m6.1m8.0m

Operating expense total

9.5m10.9m14.2m
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.3m451.3k5.4m6.5m67.7m63.4m

Accounts Receivable

5.0m201.0k

Prepaid Expenses

848.0k2.1m4.9m

Current Assets

2.7m989.3k6.2m8.3m71.5m76.8m104.1m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

108.5m96.0m

Accounts Receivable

160.0k46.0k1.0m489.0k

Prepaid Expenses

2.0m3.5m4.2m4.3m

Current Assets

120.5m110.3m123.4m112.5m
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.1m)(1.7m)(2.9m)(6.7m)(16.3m)(21.8m)(30.6m)

Depreciation and Amortization

332.0k712.0k960.0k

Accounts Payable

67.0k(169.0k)220.0k

Cash From Operating Activities

(1.4m)(26.1m)(28.6m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(16.7m)(26.2m)(11.3m)(23.4m)

Depreciation and Amortization

443.0k686.0k305.0k615.0k

Accounts Payable

530.0k516.0k2.7m1.3m

Cash From Operating Activities

(12.8m)(23.7m)21.2m8.8m
USDFY, 2013

Financial Leverage

1.1 x
Show all financial metrics

Bicycle Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
BicycleRD Limited
Bicycle Therapeutics Inc
BicycleTx Limited

Bicycle Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Bicycle Therapeutics Revenue Breakdown

Embed Graph

Bicycle Therapeutics revenue breakdown by business segment: 24.4% from Oxurion Agreement, 56.2% from Bioverativ Agreement and 19.4% from AstraZeneca Agreement

Bicycle Therapeutics Online and Social Media Presence

Embed Graph

Bicycle Therapeutics News and Updates

Steven Cohen Shifts Into A Higher Gear With Bicycle Therapeutics

Guru's firm increases stake in clinical-stage biotech

Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment

Bicycle Therapeutics Ltd. shares soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease that causes damage in the blood vessels of the retina that can harm vision. The company said the Phase 1 trial …

Bicycle Therapeutics shares slide 10.7% in trading debut

Bicycle Therapeutics shares slide 10.7% in trading debut

Bicycle Therapeutics raises $60.2 million in IPO, Ideaya Biosciences raises $50 million

Bicycle Therapeutics plc priced its initial public offering late Wednesday at $14 per American Depositary Share, selling 4.3 million shares to raise $60.2 million. The stock will start trading later Thursday on Nasdaq, under the ticker symbol "BCYC." Separately, Ideaya Biosciences priced its IPo at…

Bicycle Therapeutics Blogs

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

- Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results - Patients will be selected using prespecified tumor membrane H-scores for MT1-MMP expression CAMBRIDGE, England

Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Sep. 1, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first patient has

Bicycle Therapeutics Appoints Dr. Dominic Smethurst as Chief Medical Officer

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Aug. 11, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Dominic

Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference Content Import Wed, 08/05/2020 - 16:05 Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference August 5, 2020 at 4:05 PM EDT This release is a…

Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Content Import Wed, 08/05/2020 - 06:59 Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update August 5, 2020 at 6:59 AM EDT …

Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board

Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board Content Import Tue, 06/23/2020 - 06:59 Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board June 23, 2020 at 6:59 AM EDT This rel…
Show more

Bicycle Therapeutics Frequently Asked Questions

  • Who are Bicycle Therapeutics key executives?

    Bicycle Therapeutics's key executives are Kevin Lee, Kate Bingham and Lee Kalowski.

  • How many employees does Bicycle Therapeutics have?

    Bicycle Therapeutics has 67 employees.

  • What is Bicycle Therapeutics revenue?

    Latest Bicycle Therapeutics annual revenue is $13.8 m.

  • What is Bicycle Therapeutics revenue per employee?

    Latest Bicycle Therapeutics revenue per employee is $206 k.

  • Who are Bicycle Therapeutics competitors?

    Competitors of Bicycle Therapeutics include Kymera Therapeutics, Atara Biotherapeutics and MedDay.

  • Where is Bicycle Therapeutics headquarters?

    Bicycle Therapeutics headquarters is located at Meditrina Building, Babraham Research Campus, Babraham.

  • Where are Bicycle Therapeutics offices?

    Bicycle Therapeutics has offices in Babraham and Lexington.

  • How many offices does Bicycle Therapeutics have?

    Bicycle Therapeutics has 2 offices.